TYK Medicines Inc. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently bonded to an EGFR (mutant)-targeting moiety through a linker.
Icagen Inc. has disclosed potassium voltage-gated channel subfamily KQT member 2 (KCNQ2; Kv7.2) activators reported to be useful for the treatment of pain, Alzheimer’s disease, epilepsy, motor neuron disease, neurodevelopmental disorders, depression, tinnitus and attention deficit hyperactivity disorder, among others.
Nectin-4 antibody-drug conjugate (ADC) and checkpoint inhibitor combinations have represented a great advancement in the treatment of bladder cancer, but relapse and treatment-related toxicities underscore the need for new therapeutic strategies.
Researchers from Anaveon AG and affiliated organizations presented the discovery and preclinical characterization of ANV-700, a novel proximity-activated cytokine (PAC) compound designed to selectively deliver IL-21 to PD-1-expressing cells for the treatment of cancer.
The enzyme aminocarboxymuconate semialdehyde decarboxylase (ACMSD) is a regulator of de novo NAD+ synthesis and is reduced in patients with advanced liver disease.
Recent findings have unveiled that 15-HETE is the endogenous agonist for G protein-coupled receptor 39 (GPR39) in vascular smooth cells, so researchers hypothesized that GPR39 could work as a therapeutic target in pulmonary arterial hypertension and its deletion might prevent the development of the disease.
Researchers from the University of Washington are developing new antibiotics targeting bacterial methionyl-tRNA synthetase (MetRS). This enzyme is responsible for charging tRNA(met) with methionine and integral to protein synthesis.
Discovered and characterized at The University of North Carolina at Chapel Hill, the compound showed potent PDE4D inhibition and demonstrated high selectivity over other PDE families.
RSS
